Perspective Therapeutics (CATX) Cash from Investing Activities (2016 - 2026)

Perspective Therapeutics' Cash from Investing Activities history spans 17 years, with the latest figure at -$109.6 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 1868.61% to -$109.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$62.8 million, a 64.58% increase, with the full-year FY2025 number at $41.2 million, up 118.83% from a year prior.
  • Cash from Investing Activities hit -$109.6 million in Q1 2026 for Perspective Therapeutics, down from $28.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for CATX hit a ceiling of $28.5 million in Q4 2025 and a floor of -$138.6 million in Q4 2024.
  • Historically, Cash from Investing Activities has averaged -$19.2 million across 5 years, with a median of -$573000.0 in 2023.
  • Biggest five-year swings in Cash from Investing Activities: surged 97261.54% in 2023 and later tumbled 155632.58% in 2024.
  • Tracing CATX's Cash from Investing Activities over 5 years: stood at -$28.8 million in 2022, then soared by 99.69% to -$89000.0 in 2023, then tumbled by 155632.58% to -$138.6 million in 2024, then skyrocketed by 120.59% to $28.5 million in 2025, then tumbled by 483.9% to -$109.6 million in 2026.
  • Business Quant data shows Cash from Investing Activities for CATX at -$109.6 million in Q1 2026, $28.5 million in Q4 2025, and $14.0 million in Q3 2025.